Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America

Humberto Martinez-Cordero Honoraria: Janssen, Sanofi, Bristol Myers Squibb/Celgene, Takeda Consulting orAdvisoryRole: Janssen, Sanofi,Bristol MyersSquibb/Celgene, Takeda Travel, Accommodations, Expenses: Sanofi Camila Peña Honoraria: Janssen Consulting or Advisory Role: Janssen Travel, Accommodation...

Full description

Bibliographic Details

Main Author:	Martínez-Cordero, Humberto (author)
Other Authors:	Peña, Camila (author), Schutz, Natalia Paola (author), Bove, Virginia (author), Villano, Fiorella (author), Beltrán, Cecilia (author), Donoso, Javiera (author), López-Vidal, Hernán (author), Roa Salinas, Macarena Alejandra (author), Soto, Pablo (author), Ochoa, Paola (author), Duarte, Patricio (author), Riva, Eloísa (author)
Format:	article
Language:	English
Published:	2023
Subjects:	PERSONA DE MEDIANA EDAD PROTOCOLOS DE QUIMIOTERAPIA COMBINADA ANTINEOPLÁSICA BORTEZOMIB CICLOFOSFAMIDA DEXAMETASONA MIELOMA MÚLTIPLE PRONÓSTICO TALIDOMIDA RESULTADO DEL TRATAMIENTO USOS TERAPÉUTICOS QUIMIOTERAPIA EPIDEMIOLOGÍA
Online Access:	https://hdl.handle.net/20.500.12008/53300
Tags:	Add Tag No Tags, Be the first to tag this record!